Merck and GTx cause several Phase I and Phase II clinical trials evaluate multiple SARM product candidates including Ostarine for sarcopenia. Merck and GTx evaluating additional muscle loss indications for potential SARM clinical development.. In December 2007 GTX and Merck & Co. Formed a collaboration to discover and develop selective androgen receptor modulators , a new class of drugs that treat the potential sarcopenia, which is the loss of skeletal muscle mass, which in reduced physical strength and the ability to perform activities of daily living, cancer cachexia , and other musculoskeletal conditions cause.
Ezekowitz, senior vice president and franchise head, bone, respiratory, immunology and endocrinology, Merck Research Laboratories. – About cachexia syndrome – cancer induced muscle loss occurs in about 50 % of cancer patients and can lead to loss of protein stores, weakness and fatigue, immobility, loss of independence of and lead to the inability to tolerate and respond to cancer treatments. Cancer induced muscle wasting is responsible for at least 20 % of cancer deaths. There are no drugs currently used to treat cancer wasting approved.. No improvement in the speed or performance There were no placebo group. There were no improvements in the endpoints of grip strength and walking speed.
‘We are moving our program on SARMs are committed and look forward to continuing our work with GTx, ‘said Alan B.This study suggests the fact that acupuncture an excellent complement to other medical treatments, above all to those who treatment of the Heart system, said Dr. Longhurst, director of the Samueli centers and study leader. The western world is be wait of a clear scientific basis to the use of acupuncture, and we hope printing and will integration the integration of the old healing practices in the modern medical treatment. .
In tests on rats, the researchers found that electric acupuncture treatments temporarily down remedial action taken as of the conditions which compressed pressure in the hypertensive State. These treatments, they believe, may potentially become a part of of a therapeutic regimen to long-term care high blood pressure and others cardio diseases in humans.